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Abstract
Introduction and hypothesis Aim of this study was to
investigate the excitability of sphincter motor neurons
under the influence of pelvic floor muscle training (PFMT)
and duloxetine. Due to their mechanisms of action, there
might be a synergistic effect of duloxetine and PFMT in
regard to the facilitation of spinal reflexes controlling
urethral sphincter contractions and hence continence.
Methods In ten healthy female subjects, clitoral electric
stimulation (CES) and transcranial magnetic stimulation
(TMS) were used to determine individual motor thresholds
for external urethral sphincter (EUS) contractions before and
after PFMT, duloxetine, and PFMT + duloxetine.
Results PFMT and duloxetine alone significantly decreased
the motor thresholds for EUS contractions during CES and
TMS. However, the combined treatment reduced the motor
threshold for EUS contractions significantly stronger
compared to PFMT or duloxetine alone.
Conclusions The results are suggestive for a synergistic
facilitatory effect of PFMT and duloxetine on sphincter
motor neuron activation.
Keywords 5HT/NE reuptake inhibitors . Duloxetine .
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Introduction
Stress urinary incontinence (SUI)—defined as the com-
plaint of involuntary leakage on effort or exertion, or on
sneezing or coughing [1]—is an often bothersome symptom
that reduces the quality of life (QoL), including sexual
health [1, 2]. SUI occurs when bladder pressure exceeds
urethral closure pressure under conditions of increased
abdominal pressure. The peak incidence of SUI occurs
between 45 and 49 years of age and obesity, pregnancy, and
vaginal childbirth are recognized risk factors [2]. The
prevalence of SUI is about 50% among women with
urinary incontinence (UI) [3]. UI in women is a common
disorder and the median worldwide prevalence is indicated
with 27.6% and is considered even higher in institutional
settings [4].
Different factors can have an influence on the pathogenesis
of SUI [5] and several theories exist regarding the underlying
mechanism or dysfunction causing SUI, including urethral
hypermobility and intrinsic sphincter deficiency [6, 7], the
“backboard” or “hammock” concept [8], and the integral
theory [9]. Accordingly, there are different treatment options
correcting the assumed cause of SUI, including different
urethral sling surgeries, colposuspension, urethral bulking
agents, vaginal pessaries, and pelvic floor muscle training
(PFMT).
Drug treatment for SUI played only a subordinate role
until duloxetine, a combined serotonin and norepinephrine
reuptake inhibitor, was introduced in the treatment of SUI a
few years ago and showed promising results [10]. Its main
mechanism of action in SUI treatment is to increase the
tone of the external urethral sphincter by increased
availability of the excitatory neurotransmitters serotonin
and norepinephrine in the sacral spinal cord, where the
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sphincter motoneurons are located [11–13]. Although
PFMT, a recommended first line therapy for SUI, and
duloxetine, as a first drug of its class used in SUI, are
shown to be effective conservative treatment options, little
is known about a combined effect of both therapies.
Up to day, there is only one randomized controlled
clinical trial investigating the combined treatment of PFMT
and duloxetine in women with SUI [14]. The results
suggested an additive effect of a combined treatment. The
aim of this study was now, based on previous experience and
findings [11], to explore a possible working mechanism and
reason for the potential benefit of the combined therapy,
using neurophysiological and urodynamical measurements.
Our hypothesis is that duloxetine in combination with PFMT
has a synergistic effect on the excitability of pudendal motor
neurons, more than duloxetine or PFMT alone.
Materials and methods
After approval of the local ethics committee (Kantonale
Ethikkommission Zürich), a volunteer sample of healthy
females was recruited. Inclusion criteria are healthy
females, age 18 to 30 years. Exclusion criteria are urinary
tract infection, pregnancy, previous child birth, any current
health problem or medication, any past or current lower
urinary tract (LUT) disorder, and any allergy to duloxetine.
All subjects were informed in written and oral form and had
to provide written informed consent prior to inclusion.
Urinary tract infection and pregnancy were excluded prior
to the investigation, using urine dip stick tests.
Before starting the experiment, PFMT was explained to
the subjects in detail and correct contraction was assessed
by intravaginal manual control, requiring a maximal
contraction around the finger and a slight inward lift,
without straining and contraction of the abdominal muscles
or lifting the whole pelvis due to contraction of the buttocks.
The PFMT instruction, the exercises itself, and all other
measurements during the experiment were performed with
subjects in supine position.
The experiment consisted of four measurements, during
which the individual resting motor threshold for external
urethral sphincter (EUS) contraction in response to clitoral
electric stimulation (CES) and transcranial magnetic stim-
ulation (TMS) was determined (Fig. 1).
Prior to measurement 1, an 8-Fr Microtip catheter
(Unitip, Unisensor AG, Attikon, Switzerland) was inserted
transurethrally and the bladder was filled by 100 ml. The
urethral pressure transducer of the catheter was placed at
the point of maximum urethral pressure and fixated
properly with tape on the inside of the left thigh.
Additionally, a vaginal probe (Periform intravaginal probe,
Neen, Oldham, UK) with a length of 8 cm was placed. The
position of both the catheter and the vaginal probe was
assessed prior to each measurement or PFMT using
fluoroscopy (Fig. 2).
CES was performed using a bipolar stimulator (AS100,
ALEA Solutions GmbH, Zürich, Switzerland), which was
connected to two surface disc electrodes beside the clitoris.
The current was slowly increased until a contraction
response could be observed from the pressure transducer
at the EUS.
TMS was performed using a liquid cooled magnetic coil
(MC125, Dantec Medical A/S, Skovlunde, Denmark)
connected to a magnetic stimulator (MagPro, Dantec
Medical A/S, Skovlunde, Denmark) with a maximum
magnetic field strength of 1.8 T. During stimulation, the
coil was positioned in midline over the cranial motor cortex
and after determination of the area of best response (hot
spot), the magnetic field strength was slowly increased until
a contraction response could be observed from the pressure
transducer at the EUS. CES and TMS were repeated
alternately twice per measurement, to exclude a mutual
effect and to assess reproducibility.
Between measurement 1 and 2 and 3 and 4, PFMT was
performed for 10 min with a contraction frequency of
0.5 Hz under biofeedback monitoring (AutoMove AM800
by Danmeter A/S, Odense, Denmark) with 1 min of
training alternating with 1 min of rest (Fig. 1). All subjects
were requested to perform maximum pelvic floor muscle
contractions during the training, which was controlled via
the biofeedback display.
Between measurements 2 and 3, subjects received 40 mg
of duloxetine (Cymbalta®, Eli Lilly SA, Vernier/Genève,
Switzerland) and had a 4-h rest, during which the catheter
and vaginal probe were removed. After measurements 2
and 4, uroflowmetry and measurement of postvoid residual
volume was performed.
The mean of the two thresholds determined with CES
and TMS during each measurement were compared
Fig. 1 Experimental paradigm
and timing. M measurement,
PFMT pelvic floor muscle
training, EUS external urethral
sphincter, CES clitoral electric
stimulation, TMS transcranial
magnetic stimulation
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between the individual measurements using the Wilcoxon
signed ranks test in SPSS 14.0 (SPSS Inc. Headquarters,
233 S. Wacker Drive, 11th floor, Chicago, IL 60606, USA).
Due to multiple comparisons, α was corrected to 0.016
(Bonferroni method).
Results
Ten healthy female subjects (age 24.5±2.9 years) could be
included (Table 1). The experimental procedure was well
tolerated and all subjects completed the study. Side effects
were limited to nausea in two and tiredness in four subjects.
None of the subjects indicated pain during catheterisation,
magnetic stimulation, or electrical clitoris stimulation.
Individual motor thresholds for EUS contraction could be
obtained in response to CES and TMS during all four
measurements in all subjects (Table 1).
Effect of PFMT on the excitability of EUS neurons
(measurement 1 vs. 2)
After PFMT, the individual motor thresholds for EUS
contractions during CES and TMS were significantly lower
(Figs. 3 and 4).
Effect of duloxetine on the excitability of EUS neurons
(measurement 1 vs. 3)
Four hours after duloxetine intake, the individual motor
thresholds for EUS contractions during CES and TMS were
significantly lower (Figs. 3 and 4).
Combined effect of duloxetine and PFMT
on the excitability of EUS neurons (measurement 2
vs. 4 and 3 vs. 4)
After combined treatment with duloxetine and PFMT, the
individual motor thresholds for EUS contractions during
CES and TMS were even significantly lower compared to
PFMT or duloxetine alone (Figs. 3 and 4).
Discussion
According to our hypothesis, duloxetine and PFMT
combined significantly reduced the motor thresholds for
EUS contractions even more compared to duloxetine or
PFMT alone. PFMT in the treatment of SUI can presumably
work via three different ways: (a) conscious pelvic floor
muscle precontraction during physical stress, (b) strength
training, or/and (c) indirect training of the pelvic floor
muscles via abdominal muscle training [15]. An optimal
outcome of PFMT for SUI patients would be to reach the
automatic (unconscious) cocontraction level, which is
present in healthy continent subjects. How this result can
be obtained best, whether with option (a), (b), (c), or in
combination is still unclear [15]. The evidence for the
efficacy of indirect training via abdominal muscles (option c)
is, however, poor. To date, there is only one study comparing
PFMTwith PFMT + transversus abdominus training, finding
no benefit of adding transversus abdominus training [16].
Regarding the facilitatory neuromodulative effects of
muscle training, it could be demonstrated in several studies
that even short-term muscle training increases the excit-
ability in supraspinal and also in spinal centers [17, 18].
This is one of the first mechanisms together with
adaptations in motor unit recruitment which is involved in
the very early changes after starting muscle training [18].
The supraspinal regions involved in EUS control and
coordination of pelvic floor muscles including the EUS
have been revealed in several imaging studies using
positron emission tomography and functional magnetic
resonance imaging [19]. As our findings demonstrate,
PFMT not only decreases the motor threshold during
TMS but also during CES, which is in principle nothing
else than bulbocavernosus reflex testing. This would
possibly implicate that PFMT not only cause changes in
supraspinal regions but also in the sacral spinal cord in
regard of facilitating sacral viscerosomatic reflexes.
PFMT is yet the first line therapy for SUI, mixed urinary
incontinence, and sometimes even urgency urinary incon-
tinence and based on the available data, it seems that PFMT
is better than no treatment, placebo, or inactive control
treatments [20]. Short-term cure rates with PFMT are
encouraging with rates of 44–70% (≤2 g of urine leak on
Fig. 2 Fluoroscopy image of one subject, showing the vaginal probe
and the transurethral catheter with pressure transducers intravesical
and at the external urethral sphincter
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pad test), although no consensus exists regarding a gold
standard measure for cure [15]. It can take, however, up to
4 to 8 weeks to improve strength and/or timing of PFM
contractions and as long as 5 months to show a clinical
improvement in SUI for the patients [15, 21].
Therefore, the efficacy and long-term results of PFMT,
next to a skilled training education by a specialized
physiotherapist, very much relies on the motivation and
compliance of the patient. Compliance and motivation is
even more important as PFMT should be continued
indefinitely following a certain standardized regimen [22].
Although most studies on long-term follow-up are
difficult to compare due to differences in training regiment,
outcome measures, and long-term compliance with PFMT,
the results of some studies show that in the majority of
patients, a beneficial effect of PFMT can be maintained and
that the patients do not require surgery anymore. However,
there is still a need for a large randomized placebo-
controlled long-term study on the clinical effectiveness
and quality of life, which is in addition sufficient for
subgroup analysis [20].
Regarding the cost effectiveness, PFMT with a ratio of
€0.03/incontinence episode (IE) avoided is favorable over
duloxetine with a ratio of €3.81/IE (the underlying
calculations refer to The Netherlands. The results can not
be necessarily applied to other countries) [23].
Duloxetine is a first pharmacological therapy option for
SUI. It cannot completely cure SUI and 40 mg bid used for
SUI treatment can cause several adverse events (most
commonly: nausea, vomiting, constipation, headache, dry
mouth, fatigue, dizziness, and insomnia) appearing in
1–25% of patients receiving duloxetine in trials, which
resulted in discontinuation of the drug in about one of eight
people [10]. Although it is approved in several European
countries since August 2004 for the treatment of SUI, it is
not approved by the US Food and Drug Administration due
to safety concerns (www.fda.gov).
Nevertheless, it could be shown in several randomized
controlled trials that duloxetine is superior to placebo and
can significantly reduce incontinence and improve QoL
[10]. It has a relatively balanced combined inhibitory effect
on the synaptic reuptake of serotonin (5-hydroxytryptamin,
5-HT) and norepinephrine (NE). Although α-adrenoceptors
and 5-HT receptors can be found throughout the human
body and with high density in several areas in the spinal
cord, there is a specific high receptor density in the sacral
ventral horns of the spinal cord, in the area of the Onuf’s
nucleus, where the urethral sphincter motoneurons are
located [13]. Thor and Katofiasc could demonstrate in their
study with anesthetized cats that duloxetine was able to
decrease bladder contractions and increase bladder capacity.
This effect was even more pronounced in cat bladders,
treated with acetic acid. Additionally, duloxetine showed an
increase in muscle activity of the EUS [13]. Both effects on
bladder capacity and sphincter activity increased dose
dependently. However, systemic administration of duloxetine
did not result in inhibition or decrease of bladder contraction
evoked by direct stimulation of the pelvic nerve, which
suggests an effect of duloxetine rather in the central nervous
system than peripheral. Further studies in cats revealed that
Fig. 3 Motor thresholds for external urethral sphincter (EUS)
contractions during clitoral electric stimulation (CES). The boxplots
show minimum, 25% percentile, median, 75% percentile, and
maximum. Braces indicate significance level between the four
different measurements
Fig. 4 Motor thresholds for external urethral sphincter (EUS)
contractions during transcranial magnetic stimulation (TMS). The
boxplots show minimum, 25% percentile, median, 75% percentile, and
maximum. Braces indicate significance level between the four
different measurements
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the receptors 5-HT2 and α1 mediate the facilitation of
pudendal nerve reflexes [24, 25]. A study in humans
emphasized this conclusion in regard to the α1-receptor,
showing a decrease in rhabdosphincter electromyography
activity after administration of the α1-adrenergic receptor
antagonist prazosin, indicating that endogenous NE was
being tonically released to maintain urethral motor neuron
activity via the activation of α1-adrenoceptors [26]. Another
study in humans affirmed the results from the cat studies and
found a significant increased contractibility of the EUS
toward sacral magnetic stimulation after administration of
duloxetine [11]. The results of a recent study with a sneeze-
induced incontinence model in rats demonstrated that
duloxetine can prevent SUI by facilitating noradrenergic
and serotonergic systems in the spinal cord to enhance the
sneeze-induced urethral closure mechanism [27]. Furthermore,
the results suggested that EUS continence reflexes during
sneezing are likely to be regulated by a complex balance
among facilitatory 5-HT-receptors, α1-adrenoceptors, and
inhibitory α2-adrenoceptors [27].
That duloxetine probably has an effect on the human
sacral spinal cord could be demonstrated in this study by a
reduced threshold for EUS contractions to TMS and CES.
This finding is in accordance with previous studies and
suggests a facilitatory effect of duloxetine on pudendal
sphincter motor neurons in humans [11, 13]. How far there
is an effect of duloxetine on supraspinal centres regulating
EUS and pelvic floor muscles remains, however, unclear.
Regarding the hitherto known mechanism of action of
duloxetine and PFMT in SUI, it can be assumed that a
combination of both will show a synergistic effect in regard
to the motor neuron excitability of the EUS. Bearing in
mind the hypothesis that reaching an automatic activation
level of the pelvic floor and EUS could be an essential
component to regain continence [15], this combined
treatment with a significant reduction of the excitability
threshold might be a reasonable way to facilitate autonomic
reflex contractions in women with SUI. Furthermore,
duloxetine taken in course, rather than continuously, might
improve compliance with PFMT at the beginning, when
PFMT takes some time to show an effect and during relapse
[28]. Similar studies as described above in animal models
are lacking in humans, but those few neurophysiological
investigations in humans performed hitherto are the first
steps toward a better understanding of the improved
continence with duloxetine found in the past clinical trials.
It remains, however, a mandatory future challenge to
further explore the exact mechanism of action of duloxetine
on the human LUT and to validate a combined regimen of
PFMT and duloxetine in clinical practice.
There are some limitations of the study. First limitation
is the use of healthy subjects without SUI, which restricts
the translation of our results on women with SUI.
A second limitation is the small sample size of ten
subjects, which were investigated in a nonplacebo-
controlled nonrandomized study. However, this study
was planned as a proof of principle study and based on
these findings, randomized placebo controlled clinical
trials on patients with SUI and age-matched healthy
subjects are a necessary next step. Our intention was to
show the possible mechanism behind a combined treatment
of PFMT and duloxetine, which was demonstrated as
beneficial in a randomized placebo controlled trial by
Ghoniem et al. [14].
A third limitation is that we cannot completely exclude
an influence of the first PFMT on M3 and M4. Although
we cannot prove that the effect of the first PFMT has
been washed out before M3, we would expect at least a
similar threshold as after the first PFMT or probably a
slight return to baseline. We would not expect a further
decrease, as also clinical effects/benefits of PFMT does
not further improve on its own without further training. If
training is stopped, the effect of the training starts to
return to baseline. We therefore attribute the further
decrease to duloxetine. One might now argue that the
measurements itself might cause a reduction in motor
thresholds. That, however, is highly unlikely as cortico-
motor threshold determination using single pulse TMS is a
reproducible method with reliable outcome [29] and we
did not observe any influence on the thresholds by the
TMS or CES itself in pretests, which we performed
before the initiation of the study. A facilitation of cortical
excitability and modulation of the corticomotor threshold
can occur, if repeated TMS is used for several minutes,
whereas low frequency stimulation (1 Hz) suppresses
cortical excitability and high frequent stimulation (>5 Hz)
increases cortical excitability. Single impulses used for
threshold determination, however, did not show any
influence on cortical excitability [30]. Regarding CES,
determination of the bulbocavernosus reflex threshold just
two times during one measurement and with at least 15-min
interval between measurements, we would not expect any
facilitation.
A forth limitation is that neither CES nor TMS reflect
of course a physiological stimulation and cannot be com-
pared to or resemble a guarding pelvic floor contraction in
daily life. However, CES and TMS in combination with a
pressure transducer in the EUS are standardized, objective,
minimally invasive, and very reproducible measures of
neuronal excitability in regard to sphincter contractions
and therefore useful to investigate therapeutic influences
on the efferent pathway of the EUS. If these electro-
physiologically measured changes in our study population
have a relevant impact on the daily life, SUI in affected
women has to be further determined in randomized
clinical trials.
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Conclusion
Despite some limitations, the results of this functional study
of the female lower urinary tract under the influence of
PFMT, duloxetine, and PFMT with duloxetine combined
suggest that the combined treatment causes the lowest
excitability thresholds for EUS contractions during CES
and TMS in young healthy females. Although PFMT and
duloxetine alone significantly lowered the excitability
threshold, the best effect could be obtained with the
combination of both, which might be a possible explanation
for the synergistic mechanism of action of the combined
treatment. Reduced excitability thresholds might help to
promote continence by amplifying and/or accelerating the
EUS reflex contractions during abdominal stress. Although
results from this basic study cannot be readily translated to
a patient population with SUI, a combined treatment might
be worth to be further investigated in patients, in whom
PFMT alone is not sufficient enough or who show
difficulties with training compliance due to the prolonged
onset of effect of the PFMT.
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